Deep brain stimulation (DBS) is an established therapy for Parkinson’s Disease, essential tremor, dystonia, and epilepsy. DBS has more recently been tested in the context of treatment for major depressive disorder, anxiety, chronic pain, obsessive compulsive disorder, addiction, Alzheimer’s disease, eating disorders, and other indications. The first generation of DBS devices was only capable of applying stimulation in an open-loop, or continuous manner. A newer generation of devices allows for both sensing and stimulation in neural circuits, opening the door for long-term invasive recordings in humans in an ambulatory setting. Along with continued algorithm development and understanding of neural circuitry underlying disease, these devices have paved the way for closed-loop therapy, in which stimulation is applied in a non-continuous manner, often in response to a symptom-associated neural biomarker. While the implantation of these devices is often limited to clinical populations, they also allow for previously unattainable iEEG recordings and investigation of a wide range of behaviors in naturalistic environments.
In this Methods Collection, we feature current methods of advanced DBS in humans, such as the process by which symptom-associated biomarkers are identified, implementation of closed-loop therapy using (neural) biomarkers, and collection of neurophysiological data concurrently with behavioral and task data in the ambulatory setting using chronically implanted DBS devices. Contributions associated with any clinical indication using advanced DBS in humans are welcome.
0 Views
•
Cited by 13
•
2023
•
Kristin K. Sellers1,2, Ankit N. Khambhati1,2, Noah Stapper2,3, Joline M. Fan2,4, Vikram R. Rao2,4, Katherine W. Scangos2,3, Edward F. Chang1,2, Andrew D. Krystal2,3
1Department of Neurological Surgery, University of California, San Francisco, 2Weill Institute for Neurosciences, University of California, San Francisco, 3Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, 4Department of Neurology, University of California, San Francisco
0 Views
•
Cited by 4
•
2023
•
Jereen Kwong*1, Joanna Lin*2, Ryan Leriche*2, Thomas A. Wozny2, Ana Shaughnessy2, Ashlyn Schmitgen2, Prasad Shirvalkar3
1Anesthesiology (Division of Pain Management), University of California, San Francisco, 2Neurological Surgery and UCSF Weill Institute of Neurosciences, University of California, San Francisco, 3Anesthesiology (Division of Pain Management) and Neurological Surgery and UCSF Weill Institute of Neurosciences, University of California, San Francisco
0 Views
•
Cited by 4
•
2023
•
Gabrielle Strandquist1, Tomasz Frączek2, Tanner Dixon3, Shravanan Ravi3, Raphael Bechtold4, Daryl Lawrence5, Alicia Zeng6, Jack Gallant7, Simon Little3, Jeffrey Herron8
1Computer Science and Engineering, University of Washington, 2Neuroscience, University of Washington, 3Neurology, University of California, San Francisco, 4Bioengineering, University of Washington, 5Bioengineering, University of California, Berkeley, 6Biophysics, University of California, Berkeley, 7Psychology, University of California, Berkeley, 8Neurological Surgery, University of Washington
A combined lesion–neuromodulation murine platform to investigate neuroprotective strategies of early deep brain stimulation in Parkinsonism
Miguel Cesar Merino-Ruiz1,
Marcia Renata Mortari*2
1Sarah Network of Rehabilitation Hospitals,
2University of Brasília - Laboratory of Neuropharmacology
Identifying Markers of Disease States with Chronic Recording
Jackson Cagle1,
Theodore Wang*2,
Tiberio Araujo1,
Coralie De Hemptinne1
1Department of Neurology, University of Florida, Gainesville, Florida, USA,
2College of Medicine, University of Florida, Gainesville, Florida, USA